U.K. fines GSK $54.5 million

Britain’s competition authority has fined drugmaker GlaxoSmithKline PLC 37.6 million pounds (US$54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.